Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Identifieur interne : 000251 ( Main/Corpus ); précédent : 000250; suivant : 000252Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Auteurs : Gaurav Aggarwal ; Brandon Michael Henry ; Saurabh Aggarwal ; Sripal BangaloreSource :
- The American journal of cardiology [ 1879-1913 ] ; 2020.
English descriptors
- KwdEn :
- Adenosine Monophosphate (administration & dosage), Adenosine Monophosphate (adverse effects), Adenosine Monophosphate (analogs & derivatives), Alanine (administration & dosage), Alanine (adverse effects), Alanine (analogs & derivatives), Anti-Infective Agents (administration & dosage), Anti-Infective Agents (adverse effects), Azithromycin (administration & dosage), Azithromycin (adverse effects), Betacoronavirus (MeSH), Cardiovascular Diseases (chemically induced), Coronavirus Infections (drug therapy), Drug Combinations (MeSH), Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (adverse effects), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Lopinavir (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Ritonavir (therapeutic use).
- MESH :
- chemical , administration & dosage : Adenosine Monophosphate, Alanine, Anti-Infective Agents, Azithromycin, Enzyme Inhibitors, Hydroxychloroquine.
- chemical , adverse effects : Adenosine Monophosphate, Alanine, Anti-Infective Agents, Azithromycin, Enzyme Inhibitors, Hydroxychloroquine.
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemically induced : Cardiovascular Diseases.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- chemical , therapeutic use : Lopinavir, Ritonavir.
- Betacoronavirus, Drug Combinations, Humans, Pandemics.
Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.
DOI: 10.1016/j.amjcard.2020.04.054
PubMed: 32425199
PubMed Central: PMC7228893
Links to Exploration step
pubmed:32425199Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.</title><author><name sortKey="Aggarwal, Gaurav" sort="Aggarwal, Gaurav" uniqKey="Aggarwal G" first="Gaurav" last="Aggarwal">Gaurav Aggarwal</name><affiliation><nlm:affiliation>Jersey City Medical Center, Jersey City, New Jersey.</nlm:affiliation></affiliation></author><author><name sortKey="Henry, Brandon Michael" sort="Henry, Brandon Michael" uniqKey="Henry B" first="Brandon Michael" last="Henry">Brandon Michael Henry</name><affiliation><nlm:affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.</nlm:affiliation></affiliation></author><author><name sortKey="Aggarwal, Saurabh" sort="Aggarwal, Saurabh" uniqKey="Aggarwal S" first="Saurabh" last="Aggarwal">Saurabh Aggarwal</name><affiliation><nlm:affiliation>Unitypoint Clinic, Des Moines, Iowa.</nlm:affiliation></affiliation></author><author><name sortKey="Bangalore, Sripal" sort="Bangalore, Sripal" uniqKey="Bangalore S" first="Sripal" last="Bangalore">Sripal Bangalore</name><affiliation><nlm:affiliation>New York University School of Medicine, New York City New York. Electronic address: sripalbangalore@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32425199</idno><idno type="pmid">32425199</idno><idno type="doi">10.1016/j.amjcard.2020.04.054</idno><idno type="pmc">PMC7228893</idno><idno type="wicri:Area/Main/Corpus">000251</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000251</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.</title><author><name sortKey="Aggarwal, Gaurav" sort="Aggarwal, Gaurav" uniqKey="Aggarwal G" first="Gaurav" last="Aggarwal">Gaurav Aggarwal</name><affiliation><nlm:affiliation>Jersey City Medical Center, Jersey City, New Jersey.</nlm:affiliation></affiliation></author><author><name sortKey="Henry, Brandon Michael" sort="Henry, Brandon Michael" uniqKey="Henry B" first="Brandon Michael" last="Henry">Brandon Michael Henry</name><affiliation><nlm:affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.</nlm:affiliation></affiliation></author><author><name sortKey="Aggarwal, Saurabh" sort="Aggarwal, Saurabh" uniqKey="Aggarwal S" first="Saurabh" last="Aggarwal">Saurabh Aggarwal</name><affiliation><nlm:affiliation>Unitypoint Clinic, Des Moines, Iowa.</nlm:affiliation></affiliation></author><author><name sortKey="Bangalore, Sripal" sort="Bangalore, Sripal" uniqKey="Bangalore S" first="Sripal" last="Bangalore">Sripal Bangalore</name><affiliation><nlm:affiliation>New York University School of Medicine, New York City New York. Electronic address: sripalbangalore@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The American journal of cardiology</title><idno type="eISSN">1879-1913</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (administration & dosage)</term><term>Adenosine Monophosphate (adverse effects)</term><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Alanine (administration & dosage)</term><term>Alanine (adverse effects)</term><term>Alanine (analogs & derivatives)</term><term>Anti-Infective Agents (administration & dosage)</term><term>Anti-Infective Agents (adverse effects)</term><term>Azithromycin (administration & dosage)</term><term>Azithromycin (adverse effects)</term><term>Betacoronavirus (MeSH)</term><term>Cardiovascular Diseases (chemically induced)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Combinations (MeSH)</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Enzyme Inhibitors (adverse effects)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Lopinavir (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Ritonavir (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Anti-Infective Agents</term><term>Azithromycin</term><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Anti-Infective Agents</term><term>Azithromycin</term><term>Enzyme Inhibitors</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Drug Combinations</term><term>Humans</term><term>Pandemics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32425199</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1913</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><PubDate><Year>2020</Year><Month>08</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of cardiology</Title><ISOAbbreviation>Am. J. Cardiol.</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.</ArticleTitle><Pagination><MedlinePgn>147-150</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0002-9149(20)30489-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjcard.2020.04.054</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Jersey City Medical Center, Jersey City, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Brandon Michael</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unitypoint Clinic, Des Moines, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bangalore</LastName><ForeName>Sripal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New York University School of Medicine, New York City New York. Electronic address: sripalbangalore@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Cardiol</MedlineTA><NlmUniqueID>0207277</NlmUniqueID><ISSNLinking>0002-9149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32425199</ArticleId><ArticleId IdType="doi">10.1016/j.amjcard.2020.04.054</ArticleId><ArticleId IdType="pii">S0002-9149(20)30489-6</ArticleId><ArticleId IdType="pmc">PMC7228893</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000251 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000251 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32425199
|texte= Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32425199" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |